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Introduction {#sec005}
============

Pulmonary hypertension (PH) is a disease that can progress to right heart failure, whatever the cause, and associated with a poor prognosis \[[@pone.0221970.ref001]\]. Recently, it has been recognized as a novel threat to end stage renal disease (ESRD) patients and has become a subject of much interest. However, its pathogenesis has not been completely elucidated. The reported prevalence of PH in chronic kidney disease (CKD) patients, mostly undergoing hemodialysis, widely varied and increased with the decline of renal function \[[@pone.0221970.ref002]\]. The rate of PH was 33.7% - 52% in hemodialysis patients \[[@pone.0221970.ref003]--[@pone.0221970.ref006]\] and 12.6% - 42% in peritoneal dialysis patients \[[@pone.0221970.ref007]--[@pone.0221970.ref009]\]. However, there has not been many studies conducted with CKD patients without dialysis treatment, and the reported range of prevalence was 8.3% -71% \[[@pone.0221970.ref002], [@pone.0221970.ref004], [@pone.0221970.ref010]--[@pone.0221970.ref015]\]. The prevalence of PH increased with longer duration of dialysis treatment \[[@pone.0221970.ref010]\].

The prevalence of PH varies between reports due to the lack of consideration of fluid overload and the stage of CKD \[[@pone.0221970.ref016]\]. Fluid overload represents a crucial step in the pathophysiological pathways to PH in CKD patients. Assessment of volume status in patients with renal insufficiency is important not only for short-term volume management but also for long-term prevention of cardiovascular disease. Fluid overload is one of the predictors of mortality and morbidity. However, the traditional methods have several limitations for detecting the degree and severity of overhydration \[[@pone.0221970.ref017]\]. Recently, bioimpedance spectroscopy (BIS) performed at the bedside has gained popularity because it is a non-invasive, quick and relatively affordable method to quantitatively assess the volume status of the patient, although only a small number of studies have examined the relationship between volume status and PH \[[@pone.0221970.ref006], [@pone.0221970.ref008], [@pone.0221970.ref018], [@pone.0221970.ref019]\]. We previously reported that increased E/e´ ratio, reflecting left ventricular diastolic dysfunction (LVDD), was strongly associated with fluid overload in CKD patients \[[@pone.0221970.ref020]\]. LVDD may contribute to the development of PH by causing an elevated left atrial pressure \[[@pone.0221970.ref014]\].

Herein, we particularly focused on the relationship between volume status, estimated by multi-frequency bioimpedance and NT-proBNP, and PH in dialysis naive CKD5 patients.

Materials and methods {#sec006}
=====================

Patients and data collection {#sec007}
----------------------------

This study was initiated after receiving approval from the Institutional Review Board of Yonsei University Wonju Severance Christian Hospital (institutional review board no. CR 318087) and enrolled only the patients who provided written informed consent prior to the study. This study is an observational cross-sectional and prospective study of patients hospitalized for a renal replacement therapy plan. BIS, echocardiography, and laboratory tests were performed at the same time before the first dialysis, either hemodialysis or peritoneal dialysis. Patients with liver cirrhosis (n = 1), infection (n = 1), atrial fibrillation (n = 2), and valvular heart disease (n = 1) were excluded from the analysis. Patients (n = 8) with left ventricular ejection fraction (LVEF) less than 45% were also excluded. None of the patients had chronic respiratory disease. 137 patients were finally included in the analysis. This study was conducted in accordance with the Declaration of Helsinki.

Echocardiographic assessment {#sec008}
----------------------------

Echocardiography was performed in the harmonic imaging mode using a 3-MHz transducer and commercial ultrasound system (Vivid-7; General Electric-Vingmed, Milwaukee, WI, USA). A TRV was recorded from the parasternal or apical window with the continuous wave Doppler probe. The left atrial (LA) dimension was measured by 2D-guided M-mode echocardiography using the parasternal short-axis view at the base of the heart. Three LA dimensions were used to calculate the LA volume as an ellipse using the formula: LA volume = (π/6)(SA1×SA2×LA), where SA1 is the M-mode LA dimension, and SA2 and LA are measurements of the short- and long-axis with the apical four-chamber view at ventricular end-systole, respectively. The LA volume index (LAVI) was calculated by dividing LA volume by body surface area (BSA) using the formula as follows: BSA = 0.007184 × weight^0.425^× height^0.725^ (m^2^). LV internal dimensions, LV wall thickness, and LVEF, measured using the biplane modified Simpson rule, according to the previously reported recommendations \[[@pone.0221970.ref021]\]. LV mass was calculated following American Society of Echocardiography recommendations as LV mass (g) = 1.04×(\[PWTd+SWTd+LVDd\]^3^×\[LVEDD\]^3^)×0.8+0.6, where PWTd and SWTd are the posterior and septal wall thickness at end-diastole respectively, and LVEDD is the M-mode LV dimension with the short axis view at end-diastole. To correct for body surface area, the LV mass index (LVMI) was calculated as LV mass/BSA. As recommended by the Heart Failure and Echocardiography Associations of European Society of Cardiology, both conventional and tissue Doppler imaging (TDI) echocardiographic techniques were used for the evaluation of LV diastolic function \[[@pone.0221970.ref022]\].

The maximal TRV (TRVmax) greater than or equal to 2.9 m/s, corresponding to systolic pulmonary artery pressure (SPAP) of approximately 36 mmHg, was used as a definition of a high possibility of PH (PH group) \[[@pone.0221970.ref023]\]. Echocardiography was performed by trained cardiologists who were completely blinded to the patient information. The intra-class correlation coefficient of intra- and inter-observer variability in measurement of TRVmax was 98.9% and 98.0%.

Assessment of the volume status {#sec009}
-------------------------------

Bioimpedance spectroscopy using the BCM^TM^ (Body Composition Monitoring^TM^, Fresenius Medical Care, Bad Homburg, Germany) was performed prior to any dialysis treatment. BCM^TM^ utilizes alternating electric currents across 50 different frequencies from 5 to 1000 kHz for the measurement of fluid status. Extracellular water (ECW), intracellular water (ICW) and total body water (TBW) were automatically calculated. The overhydration (OH) value can be calculated from the difference between the normal ECW and actual measured ECW \[[@pone.0221970.ref024]\]. OH/ECW greater than or equal to 15% was defined as fluid overload \[[@pone.0221970.ref020]\]. Patients were in supine position. Disposable electrode patches were used for all measurements.

Laboratory evaluations {#sec010}
----------------------

All laboratory studies were performed before the first dialysis application. NT-proBNP, which is known to reflect volume status, was also measured, and the association with the possibility of PH was analysed. NT-proBNP was measured using electrochemiluminescence immunoassay (ECLIA) on Modular analytics E170 (Roche Diagnostics, Mannheim, Germany). The analytical measurement range for NT-proBNP was 5 to 35,000 pg/mL. In the correlation analysis, it was not appropriate to use the NT-proBNP value because accurate values of less than 5 pg/mL or greater than 35,000 pg/mL could not be obtained. Therefore, patients were divided into three groups in accordance with tertiles of NT-proBNP for the analysis.

Statistical analysis {#sec011}
--------------------

All analyses were performed with IBM Statistics Package for the Social Science version 23.0 (IBM Corporation, Armonk, NY, USA). The study population characteristics are presented as the mean ± SD, median (IQR), or total number (percentage). Based on the results of TRVmax, the patients were categorized into two groups according to the presence of the possibility of PH. Differences in clinical variables between the two groups were tested with two-sample t-test for continuous variables. The nominal variables were compared using Chi-square test or Fisher's exact test as appropriate. Pearson's correlation analysis was used to examine correlations between TRVmax and other variables such as volume markers (OH/ECW, NT-proBNP) and echocardiographic variables. Multivariate logistic regression models was used to examine the associations of OH/ECW and NT-proBNP with TRVmax. The C-statistics was utilized to test the predictive accuracy of a logistic regression model. Goodness of fit for model was assessed using the Hosmer-Lemeshow test, whereby we considered a value of P \< 0.05 to indicate that the model had a poor fit. In this analysis, we adjusted for age and sex (model 1) and for diuretics use and albumin (model 2). Finally, a receiver operating characteristic (ROC) curve was created to establish cut-off values of OH and OH/ECW that discriminate patients with TRVmax ≥ 2.9 m/s from those with TRVmax \< 2.9 m/s. Statistical significance was defined as P \< 0.05.

Results {#sec012}
=======

Patients' characteristics {#sec013}
-------------------------

The characteristics of the study population are shown in [Table 1](#pone.0221970.t001){ref-type="table"}. Patients with the possibility of PH (TRVmax ≥ 2.9 m/s) were less commonly treated with diuretics (P = 0.006). PH group had significantly lower estimated glomerular filtration rate. The age and gender were similar. The mean age of male and female patients was 59.99 ± 13.09 years and 59.90 ± 11.80 years, respectively. The median \[interquartile range (IQR)\] OH and OH/ECW were 2.0 (0.5--5.2) L and 13.48 (4.11--27.70) %, respectively. The median NT-proBNP was 2,570.0 (759.2--9,200.5) pg/ml.

10.1371/journal.pone.0221970.t001

###### Demographic findings of study patients.

![](pone.0221970.t001){#pone.0221970.t001g}

  Variables                       Total (N = 137)   TRVmax         P-value        
  ------------------------------- ----------------- -------------- -------------- -------
  Age, years                      59.95±12.52       66.75±12.40    56.70±12.73    0.133
  Sex Men                         80 (58.4%)        65 (59.1%)     15 (55.6%)     0.738
  Women                           57 (41.6%)        45 (40.1%)     12 (44.4%)     
  BMI (kg/m^2^)                   24.51±3.98        24.26±3.84     25.56±4.45     0.128
  Diabetes Yes                    79 (57.7%)        59 (53.6%)     20 (74.1%)     0.054
  Non diabetic renal disease      58 (42.3%)        51 (46.4%)     7 (25.9%)      
  Hypertension                    13                11             2              
  CGN                             13                12             1              
  FSGS                            4                 4              \-             
  IgAN                            7                 4              3              
  MGN                             1                 1              \-             
  MPGN                            1                 \-             1              
  Hereditary/congenital disease   6                 6              \-             
  Other                           4                 4              \-             
  Unknown                         9                 9              \-             
  BP medication            Yes    129 (94.2%)       102 (92.7%)    27 (100.0%)    0.355
  No                              8 (5.8%)          8 (7.3%)       0 (0.0%)       
  Diuretics            Yes        91 (66.4%)        67 (60.9%)     24 (88.9%)     0.006
  No                              46 (33.6%)        43 (39.1%)     3 (11.1%)      
  SBP (mmHg)                      143.73±19.42      143.73±19.42   143.73±19.42   0.090
  DBP (mmHg)                      79.60±11.62       79.60±11.62    79.60±11.62    0.609
  eGFR (mL/min/1.73 m^2^)         6.87±2.63         7.09±2.77      6.02±1.72      0.014

CGN: chronic glomerulonephritis; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; FSGS: focal segmental glomerulosclerosis; IgAN: immunoglobulin A nephropathy; MGN: membranous glomerulonephritis; MPGN: membranoproliferative glomerulonephritis; SBP: systolic blood pressure; TRVmax: maximal tricuspid regurgitation velocity.

Differences according to *TRVmax* {#sec014}
---------------------------------

Among the BIS parameters, extracellular water/intracellular water ratio (E/I ratio), ECW, OH, and OH/ECW were significantly greater in PH group. Serum parameters were not different between the two groups except iPTH and NT-proBNP ([Table 2](#pone.0221970.t002){ref-type="table"}). NT-proBNP was significantly higher in patients with the possibility of PH compared to those without PH. Among the echocardiographic parameters, the LA dimension, LAVI, E velocity, and E/e´ ratio were significantly greater in PH group, while the A velocity, e´ velocity, and LVEF were not significantly different.

10.1371/journal.pone.0221970.t002

###### Compared parameters (laboratory, bioimpedence and echocardiography) according to binary TRVmax.

![](pone.0221970.t002){#pone.0221970.t002g}

  -------------------------------------------------------------------------------------------------------------------------
  variables                                                  Total (N = 137)   TRVmax          P-value           
  ---------------------------------------------------------- ----------------- --------------- ----------------- ----------
  OH (liter)                                                 3.26±4.11         2.63±3.91       5.84±3.94         \< 0.001

  OH/ECW (%)                                                 15.75±15.96       13.09±15.05     26.76±15.07       \< 0.001

  E/I ratio                                                  1.01±0.22         0.98±0.20       1.14±0.23         \< 0.001

  ECW (liter)                                                16.98±5.06        16.24±4.75      19.98±5.26        \< 0.001

  ICW (liter)                                                16.90±3.97        16.70±3.88      17.74±4.28        0.221

  TBW (liter)                                                33.80±8.17        32.94±7.76      37.33±8.99        0.012

  LA dimension (cm)                                          4.70±0.48         4.63±0.44       4.99±0.52         \< 0.001

  LAVI (ml/m^2^)                                             38.90±11.12       36.21±9.06      49.85±12.13       \< 0.001

  E (m/s)                                                    0.84±0.31         0.75±0.24       1.20±0.31         \< 0.001

  A (m/s)                                                    1.00±0.29         1.00±0.22       1.00±0.48         0.943

  e´ (m/s)                                                   0.06±0.02         0.05±0.02       0.06±0.02         0.078

  E/e´ ratio                                                 15.85±5.65        14.58±4.20      20.96±7.66        \< 0.001

  LVEDD (cm)                                                 5.42±0.53         5.36±0.53       5.66±0.47         0.008

  LVEDV (ml)                                                 144.99±31.10      141.59±30.54    158.85±30.01      0.009

  LVMI (g/m^2^)                                              118.78±30.84      115.34±30.94    132.82±26.60      0.008

  LVEF (%)                                                   63.95±5.93        63.99±5.82      63.78±6.46        0.868

  NT-proBNP, (pg/mL) [\*](#t002fn001){ref-type="table-fn"}   2,570\            1,973\          10,112\           \< 0.001
                                                             (759--9,201)      (592--7,686)    (4,153--35,000)   

  Hemoglobin (g/dL)                                          9.10±1.31         9.18±1.37       8.77±0.99         0.143

  Protein (g/dL)                                             6.16±0.77         6.21±0.80       5.96±0.61         0.126

  Albumin (g/dL)                                             3.47±0.58         3.51±0.60       3.34±0.47         0.178

  Cholesterol (mg/dL)                                        151.90±48.71      151.00±50.20    158.00±42.30      0.489

  Triglyceride (mg/dL)                                       123.60±73.32      125.70±74.55    115.20±68.79      0.507

  HDL (mg/dL)                                                40.00±14.31       39.23±14.05     43.24±15.23       0.209

  LDL (mg/dL)                                                87.27±42.43       86.38±40.02     91.00±35.50       0.627

  iPTH (pg/mL)                                               308.06±206.84     319.26±225.25   260.65±83.20      0.032

  Calcium (mg/dL)                                            7.66±1.10         7.74±1.14       7.30±0.81         0.062

  Phosphorus (mg/dL)                                         5.96±1.60         5.93±1.60       6.09±1.61         0.655

  Uric acid (mg/dL)                                          8.10±2.46         8.10±2.39       8.10±2.79         1.000

  Magnesium (mg/dL)                                          2.32±0.48         2.28±0.48       2.47±0.48         0.079

  TSAT (%)                                                   30.96±16.42       32.33±17.54     25.35±8.93        0.067
  -------------------------------------------------------------------------------------------------------------------------

\* Median (Interquartile range)

ECW: extracellular water; E/I: extracellular water/ intracellular water; HDL: High-density lipoprotein; iPTH: intact parathyroid hormone; ICW: intracellular water; LA: left atrium; LAVI: left atrium volume index; LDL: low-density lipoprotein; LVEDD: left ventricular end-diastolic dimension; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVMI: left ventricular mass index; NT-proBNP: N-terminal pro-hormone of brain natriuretic peptide; OH: overhydration; TBW: total body water; TRVmax: maximal tricuspid regurgitation velocity; TSAT: transferrin saturation.

Correlation between laboratory, echocardiographic parameters and markers of volume status {#sec015}
-----------------------------------------------------------------------------------------

TRVmax was correlated with volume marker (OH, OH/ECW, E/I ratio). OH/ECW was significantly associated with LAVI, E velocity, E/e´ ratio, LVEDD, and LVEDV ([Table 3](#pone.0221970.t003){ref-type="table"}).

10.1371/journal.pone.0221970.t003

###### Correlation between laboratory, echocardiographic parameters and markers of volume status.

![](pone.0221970.t003){#pone.0221970.t003g}

                         TRVmax   OH/ECW              
  ---------------------- -------- ---------- -------- ----------
  SBP (mmHg)             0.115    0.182      0.235    0.006
  DBP (mmHg)             -0.042   0.629      0.189    0.027
  Total Protein (g/dL)   -0.137   0.110      -0.510   \< 0.001
  Albumin (g/dL)         -0.141   0.101      -0.551   \< 0.001
  iPTH (pg/mL)           -0.163   0.057      -0.253   0.003
  OH (liter)             0.189    0.027      0.920    \< 0.001
  OH/ECW (%)             0.235    0.006      \-       \-
  E/I ratio              0.185    0.031      0.861    \< 0.001
  ECW (liter)            0.165    0.055      0.733    \< 0.001
  ICW (liter)            0.059    0.495      0.075    0.383
  TBW (liter)            0.123    0.151      0.492    \< 0.001
  LA dimension (cm)      0.300    \< 0.001   0.253    0.003
  LAVI (ml/m^2^)         0.450    \< 0.001   0.368    \< 0.001
  E (m/s)                0.483    \< 0.001   0.461    \< 0.001
  A (m/s)                -0.107   0.216      0.049    0.571
  e´ (m/s)               0.174    0.043      0.167    0.052
  E/e´ ratio             0.329    \< 0.001   0.322    \< 0.001
  LVEDD (cm)             0.172    0.044      0.228    0.007
  LVEDV (ml)             0.185    0.030      0.242    0.004
  LVMI (g/m^2^)          0.223    0.009      0.157    0.066
  LVEF (%)               0.153    0.074      -0.094   0.274
  TRVmax (m/s)           \-       \-         0.235    0.006

Corr. coeff., correlation coefficient

ECW: extracellular water; E/I: extracellular water/ intracellular water; DBP: diastolic blood pressure; iPTH: intact parathyroid hormone; ICW: intracellular water; LA: left atrium; LAVI: left atrium volume index; LVEDD: left ventricular end-diastolic dimension; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVMI: left ventricular mass index; OH: overhydration; SBP: systolic blood pressure; TBW: total body water; TRVmax: maximal tricuspid regurgitation velocity.

Multivariate analysis using logistic regression {#sec016}
-----------------------------------------------

Among the significantly different variables between the two groups, OH/ECW and NT-proBNP were associated with TRVmax in unadjusted model. These variables were chosen considering the collinearity among the factors. OH/ECW was divided into two groups: OH/ECW \<15%, and OH/ECW ≥15% (fluid overload). We also categorized NT-proBNP as tertiles (\<1,204.62 pg/mL, 1,204.62\~6,931.55 pg/mL, \>6,931.55 pg/mL). Odds ratio was calculated using the lowest tertile as the reference.

The fluid overloaded group showed significant odds ratio in model 2 whereas the highest NT-proBNP group showed significant odds ratio in model 1 and model 2 ([Table 4](#pone.0221970.t004){ref-type="table"}). The Hosmer--Lemeshow tests showed significant goodness of fit for model 1 (P = 0.061) and model 2 (P = 0.958). Model 2 showed high capacity for predicting the high risk of PH group. The c-statistic was 0.769 (95% CI 0.676 \~0.861, P \< 0.001) and 0.788 (95% CI 0.695 \~0.880, P \< 0.001) for model 1 and model 2, respectively.

10.1371/journal.pone.0221970.t004

###### Multivariate analysis using logistic regression: Predictive factors for the risk of pulmonary hypertension group.

![](pone.0221970.t004){#pone.0221970.t004g}

  ---------------------------------------------------------------------------------------------------------------------------
  variables               Univariate analysis      Model 1    Model 2                                                 
  ----------------------- ------------------------ ---------- ----------------------- ------- ----------------------- -------
  OH/ECW                                                                                                              

  \<15 (%)                Reference                           Reference                       Reference               

  ≥15 (%)                 5.453 (2.037\~14.601)    \< 0.001   2.860 (0.920\~8.889)    0.069   3.463 (2.037\~14.601)   0.049

  NT-proBNP                                                                                                           

  \<1,204 (pg/mL)         Reference                           Reference                       Reference               

  1,204\~ 6,931 (pg/mL)   5.230 (1.062\~25.747)    0.042      3.931 (0.729\~21.211)   0.111   4.530 (0.805\~25.495)   0.087

  \> 6,931 (pg/mL)        11.862 (2.534\~55.530)   0.002      6.055 (1.113\~32.949)   0.037   6.184\                  0.039
                                                                                              (1.094\~34.956)         
  ---------------------------------------------------------------------------------------------------------------------------

Model 1: Adjusted for age and sex.

Model 2: Adjusted for age, sex, diuretics use, and albumin.

CI, confidence interval; OR, odds ratio

ECW: extracellular water; NT-proBNP: N-terminal pro-hormone of brain natriuretic peptide; OH: overhydration.

Discussion {#sec017}
==========

The pathogenesis of PH in ESRD patients is still complex and not completely understood. Several factors, such as fluid overload, arteriovenous fistula, anemia, hypoalbuminemia, cardiac dysfunction, mineral bone disease (MBD), uremic vasculopathy, and non-biocompatible dialysis membranes, have been proposed for the development of PH in dialysis patients \[[@pone.0221970.ref008], [@pone.0221970.ref025]--[@pone.0221970.ref027]\]. Different from other previous reports, albumin and hemoglobin levels and markers of CKD-MBD were not associated with the possibility of PH in this study \[[@pone.0221970.ref009], [@pone.0221970.ref028]\]. In addition, because the patients were dialysis naïve CKD, the arteriovenous fistulae and dialysis membrane components, which were associated with PH in other studies, were excluded in this study \[[@pone.0221970.ref014], [@pone.0221970.ref015], [@pone.0221970.ref029], [@pone.0221970.ref030]\].

Serum NT-proBNP levels is a biochemical marker for estimating the volume status and is associated with LV diastolic dysfunction \[[@pone.0221970.ref031]\]. In the present study, we found that E/e´ ratio, a marker of diastolic dysfunction, was associated with volume status and significantly correlated with NT-proBNP and TRVmax. Tissue Doppler e´ velocity, which is an element of E/e´ ratio, was related to TRVmax but not to OH/ECW and NT-proBNP. E velocity was associated with TRVmax, OH/ECW, and NT-proBNP, and there was a significant difference between the patients with or without PH, whereas e´ velocity was not. These findings are in line with the study that E velocity is associated with the circulating volume of hemodialysis patients \[[@pone.0221970.ref032]\]. On the other hand, A velocity was not related to all three factors. Diastolic dysfunction may contribute to the development of PH by causing an elevated left atrial pressure \[[@pone.0221970.ref012], [@pone.0221970.ref014], [@pone.0221970.ref023]\]. Progressive fluid overload with diastolic dysfunction could increase pulmonary capillary wedge pressure, which may result in PH. The right ventricle with thin muscle equipment usually operates at low blood pressure and is not able to tolerate high vascular resistance. Once the right heart chambers lose their distensibility due to an elevated left atrial pressure, it leads to tricuspid regurgitation and further right heart volume overload \[[@pone.0221970.ref033]\]. PH might be induced and/or aggravated by left heart disease. Because we excluded patients with systolic dysfunction, the main factor would probably be the diastolic dysfunction. Therefore, volume overload is critical to determining TRVmax.

Since the symptoms and signs of PH are somewhat ambiguous, nephrologists rarely suspect PH at the beginning of treatment in the patients with CKD \[[@pone.0221970.ref034]\]. Clinically, an indication of diuretic therapy is given when the patient complains of the signs and symptoms of fluid overload. It is not common clinical practice to prophylactically administer diuretics prior to diagnosis of PH. Nevertheless, in this study, diuretics were given to many PH patients (88.9%). However, as this study was conducted retrospectively, we could not confirm whether there was a need for the clinicians to prescribe diuretics in suspicion of PH. Furthermore, patients with PH demonstrated more frequent diabetes, and 95% (19 patients) of these patients were on diuretics. Endothelial dysfunction and increased arterial stiffness may occur in early diabetic CKD and so forth fluid overload may occur subsequently and have an effect on left ventricular systolic and/or diastolic dysfunction in late diabetic CKD. Therefore, the authors conclude that the presence of diabetes may have an effect on PH, but the numbers of cases included in this study are small so further studies and analysis with larger numbers of patients, divided into the early and late stage, is needed. In general, the diagnosis of PH can be made in collaboration with a cardiologist with the consideration of two things. The first is that the right heart catheterization should be performed by a skillful specialist because of the invasive nature of the procedure, and the need for a special space equipped with special instruments. The second issue is whether volume control can improve PH, because volume overload is a modifiable factor. However, when CKD5 patients initiate incident dialysis, a comprehensive approach should be implemented because there are factors that can induce PH other than fluid overload.

We could not confirm the change of SPAP by volume control after initiating dialysis. However, since volume control is a reversible factor, improvement of PH can be expected by correcting it. In fact, Yilmaz *et al*. reported that the SPAP, OH/ECW, and the frequency of PH were significantly reduced after hemodialysis treatment \[[@pone.0221970.ref006]\]. BIS can be useful as a tool for this, which enables treatments targeting not only PH but also LVDD \[[@pone.0221970.ref035]\]. An OH/ECW of 15% is thought to represent approximately 2.4 liters of overhydration and is used as a cut-off value for overhydration. In our previous report, the cut-off value for OH and OH/ECW predicting E/e´ ratio greater than 15 was 2.45 liters and 17.28%, respectively \[[@pone.0221970.ref031]\]. Furthermore, ROC curves were drawn for OH and OH/ECW to determine the cut-off values predicting TRVmax ≥ 2.9 m/s. The area under curve (AUC ± standard error) and cut-off value were as follows: 0.754 ± 0.057 (P \< 0.001) and 4.1 liters (sensitivity 74.1%, specificity 80.0%) for OH; 0.746 ± 0.058 (P \< 0.001) and 22.66% (sensitivity 74.1%, specificity 80.9%) for OH/ECW ([Fig 1](#pone.0221970.g001){ref-type="fig"}). If the fluid overload is above a certain level, it is better to recognize the need for echocardiography and to confirm the presence or absence of PH. Despite the correction of fluid overload with dialysis treatment, it is desirable to consider kidney transplantation rather than dialysis treatment in patients with irreversible PH \[[@pone.0221970.ref036], [@pone.0221970.ref037]\]. At this stage, the role of cardiologist in determining the mode of renal replacement therapy is crucial.

![Receiver operating characteristics (ROC) curves of OH and OH/ECW for predicting the possibility of PH (TRVmax ≥ 2.9 m/s).\
Areas under the curve: OH 0. 754 (95% CI 0.643--0.866) and OH/ECW 0.746 (95% CI 0.633--0.860).](pone.0221970.g001){#pone.0221970.g001}

As a limitation of our study, this was a single-center study that included a relatively small number of patients. Furthermore, although SPAP may increase with age and in obesity, weight or body mass index was not adjusted for multivariate logistic regression models. Also, the lack of serial echocardiograms to assess changes in cardiac structure and function over time in relation to the volume control by renal replacement therapy, even though the definition of PH by echocardiography used in this study has limited sensitivity and specificity. Therefore, the mechanism by which fluid overload contributes to PH could not be proven in our study. Finally, although it could have given us important clues to our hypothesis, we did not perform the mandatory procedure, right heart catheterization, for diagnosis confirmation. Despite these limitations, the strength of this study is that we had objectively measured the volume status and concurrently have blindly evaluated SPAP. The study population was relatively homogenous and the patients were mostly enrolled to the study before making the arteriovenous fistula. As far as we know, this is the first study to have attempted in dialysis naïve CKD patients.

Taken together, a significant number of patients showed increased SPAP, which was closely related to volume status in CKD5-ND patients. Therefore, echocardiography and BIS could play an important role in PH detection and treatment of asymptomatic CKD patients. Our study suggests the need for calculation and follow-up of pulmonary artery pressure using Doppler echocardiography in all patients with established CKD5-ND before considering the dialysis treatment. If possible, it is advisable to perform the right heart catheterization in order to confirm PH. These process could be helpful to improve the cardiac outcomes after initiating renal replacement therapy.

Supporting information {#sec018}
======================

###### Dataset: Demographic, laboratory, bioimpedence, and echocardiographic data.

(XLSX)

###### 

Click here for additional data file.

DBP

:   diastolic blood pressure

eGFR

:   estimated glomerular filtration rate

ECW

:   extracellular water

ICW

:   intracellular water

LAVI

:   left atrium volume index

LVEDD

:   left ventricular end-diastolic dimension

LVEDV

:   left ventricular end-diastolic volume

LVDD

:   left ventricular diastolic dysfunction

LVEF

:   left ventricular ejection fraction

LVMI

:   left ventricular mass index

NT-proBNP

:   N-terminal pro-hormone of brain natriuretic peptide

OH

:   overhydration

PH

:   pulmonary hypertension

SBP

:   systolic blood pressure

SPAP

:   systolic pulmonary artery pressure

TBW

:   otal body water

TRV

:   tricuspid regurgitation velocity
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